PURPOSE: Controversy endures regarding the optimal treatment of patients with brain metastases (BMs). Debate persists, despite many randomized trials, perhaps because BM patients are a heterogeneous population. The purpose of the present study was to identify significant diagnosis-specific prognostic factors and indexes (Diagnosis-Specific Graded Prognostic Assessment [DS-GPA]). METHODS AND MATERIALS: A retrospective database of 5,067 patients treated for BMs between 1985 and 2007 was generated from 11 institutions. After exclusion of the patients with recurrent BMs or incomplete data, 4,259 patients with newly diagnosed BMs remained eligible for analysis. Univariate and multivariate analyses of the prognostic factors and outcomes by primary site and treatment were performed. The significant prognostic factors were determined and used to define the DS-GPA prognostic indexes. The DS-GPA scores were calculated and correlated with the outcomes, stratified by diagnosis and treatment. RESULTS: The significant prognostic factors varied by diagnosis. For non-small-cell lung cancer and small-cell lung cancer, the significant prognostic factors were Karnofsky performance status, age, presence of extracranial metastases, and number of BMs, confirming the original GPA for these diagnoses. For melanoma and renal cell cancer, the significant prognostic factors were Karnofsky performance status and the number of BMs. For breast and gastrointestinal cancer, the only significant prognostic factor was the Karnofsky performance status. Two new DS-GPA indexes were thus designed for breast/gastrointestinal cancer and melanoma/renal cell carcinoma. The median survival by GPA score, diagnosis, and treatment were determined. CONCLUSION: The prognostic factors for BM patients varied by diagnosis. The original GPA was confirmed for non-small-cell lung cancer and small-cell lung cancer. New DS-GPA indexes were determined for other histologic types and correlated with the outcome, and statistical separation between the groups was confirmed. These data should be considered in the design of future randomized trials and in clinical decision-making. (c) 2010 Elsevier Inc. All rights reserved.
PURPOSE: Controversy endures regarding the optimal treatment of patients with brain metastases (BMs). Debate persists, despite many randomized trials, perhaps because BM patients are a heterogeneous population. The purpose of the present study was to identify significant diagnosis-specific prognostic factors and indexes (Diagnosis-Specific Graded Prognostic Assessment [DS-GPA]). METHODS AND MATERIALS: A retrospective database of 5,067 patients treated for BMs between 1985 and 2007 was generated from 11 institutions. After exclusion of the patients with recurrent BMs or incomplete data, 4,259 patients with newly diagnosed BMs remained eligible for analysis. Univariate and multivariate analyses of the prognostic factors and outcomes by primary site and treatment were performed. The significant prognostic factors were determined and used to define the DS-GPA prognostic indexes. The DS-GPA scores were calculated and correlated with the outcomes, stratified by diagnosis and treatment. RESULTS: The significant prognostic factors varied by diagnosis. For non-small-cell lung cancer and small-cell lung cancer, the significant prognostic factors were Karnofsky performance status, age, presence of extracranial metastases, and number of BMs, confirming the original GPA for these diagnoses. For melanoma and renal cell cancer, the significant prognostic factors were Karnofsky performance status and the number of BMs. For breast and gastrointestinal cancer, the only significant prognostic factor was the Karnofsky performance status. Two new DS-GPA indexes were thus designed for breast/gastrointestinal cancer and melanoma/renal cell carcinoma. The median survival by GPA score, diagnosis, and treatment were determined. CONCLUSION: The prognostic factors for BM patients varied by diagnosis. The original GPA was confirmed for non-small-cell lung cancer and small-cell lung cancer. New DS-GPA indexes were determined for other histologic types and correlated with the outcome, and statistical separation between the groups was confirmed. These data should be considered in the design of future randomized trials and in clinical decision-making. (c) 2010 Elsevier Inc. All rights reserved.
Authors: Carsten Nieder; Anca L Grosu; Oddvar Spanne; Nicolaus H Andratschke; Hans Geinitz Journal: Clin Exp Metastasis Date: 2012-05-27 Impact factor: 5.150
Authors: Paul W Sperduto; Wen Jiang; Paul D Brown; Steve Braunstein; Penny Sneed; Daniel A Wattson; Helen A Shih; Ananta Bangdiwala; Ryan Shanley; Natalie A Lockney; Kathryn Beal; Emil Lou; Thomas Amatruda; William A Sperduto; John P Kirkpatrick; Norman Yeh; Laurie E Gaspar; Jason K Molitoris; Laura Masucci; David Roberge; James Yu; Veronica Chiang; Minesh Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2017-03-29 Impact factor: 7.038
Authors: Denise Bernhardt; Sebastian Adeberg; Farastuk Bozorgmehr; Nils Opfermann; Juliane Hoerner-Rieber; Laila König; Jutta Kappes; Michael Thomas; Felix Herth; Claus Peter Heußel; Arne Warth; Jürgen Debus; Martin Steins; Stefan Rieken Journal: J Neurooncol Date: 2017-05-30 Impact factor: 4.130
Authors: Diandra N Ayala-Peacock; Ann M Peiffer; John T Lucas; Scott Isom; J Griff Kuremsky; James J Urbanic; J Daniel Bourland; Adrian W Laxton; Stephen B Tatter; Edward G Shaw; Michael D Chan Journal: Neuro Oncol Date: 2014-02-20 Impact factor: 12.300
Authors: Michela Buglione; Sara Pedretti; Stefano Gipponi; Luciano Buttolo; Paolo Panciani; Pietro Luigi Poliani; Roberto Liserre; Paolo Borghetti; Ludovica Pegurri; Loredana Costa; Luca Triggiani; Nadia Pasinetti; Paolo Ghirardelli; Sara Pandini; Alessandro Padovani; Stefano Maria Magrini Journal: Radiol Med Date: 2015-04-28 Impact factor: 3.469
Authors: Tony J C Wang; Shumaila Saad; Yasir H Qureshi; Ashish Jani; Tavish Nanda; Andrew M Yaeh; Tzlil Rozenblat; Michael B Sisti; Jeffrey N Bruce; Guy M McKhann; Jeraldine Lesser; Balazs Halmos; Mark B Stoopler; Andrew B Lassman; Simon K Cheng; Steven R Isaacson Journal: Neuro Oncol Date: 2015-04-24 Impact factor: 12.300
Authors: Emory R McTyre; Adam G Johnson; Jimmy Ruiz; Scott Isom; John T Lucas; William H Hinson; Kounosuke Watabe; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William A Sperduto; Emil Lou; Ashlyn Everett; Drexell H Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; Yi An; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta Journal: J Clin Oncol Date: 2020-09-15 Impact factor: 44.544